Bio-Rad Laboratories (India) Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 3.00 M
as on 16-11-2024
- Company Age 28 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -0.21%
(FY 2023)
- Profit -79.88%
(FY 2023)
- Ebitda -73.41%
(FY 2023)
- Net Worth 7.90%
(FY 2023)
- Total Assets 30.44%
(FY 2023)
About Bio-Rad Laboratories (India)
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Norman Schwartz, Jennifer Tweet, and Brijender Kumar serve as directors at the Company.
- CIN/LLPIN
U32109HR1996PTC107956
- Company No.
078494
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurugram, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Bio-Rad Laboratories (India) Private Limited offer?
Bio-Rad Laboratories (India) Private Limited offers a wide range of products and services, including Beads, Resin Beads, Pathology Lab Equipments, Microplate Reader, Industrial Mixers & Homogenizers, Homogenizer, Flavours & Aromatics, Food Emulsifiers, Natural and Synthetic Resins, Resins.
Who are the key members and board of directors at Bio-Rad Laboratories (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jennifer Tweet  | Director | 16-Feb-2016 | Current |
| Norman Schwartz | Director | 25-Apr-1996 | Current |
Brijender Kumar  | Director | 07-Jul-2014 | Current |
Financial Performance and Corporate Structure Insights of Bio-Rad Laboratories (India).
Bio-Rad Laboratories (India) Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.21% decrease. The company also saw a substantial fall in profitability, with a 79.88% decrease in profit. The company's net worth moved up by a moderate rise of 7.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bio-Rad Laboratories (India)?
In 2023, Bio-Rad Laboratories (India) had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bio-Rad Laboratories (India)?
Bio-Rad Laboratories (India) has a workforce of 194 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bio-Rad Laboratories (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bio-Rad Laboratories (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
